Amylyx PharmaceuticalsAMLX
About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Employees: 384
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11.96% less ownership
Funds ownership: 76.11% [Q1] → 64.15% (-11.96%) [Q2]
17% less funds holding
Funds holding: 143 [Q1] → 118 (-25) [Q2]
34% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 44
44% less capital invested
Capital invested by funds: $147M [Q1] → $82.9M (-$64.4M) [Q2]
45% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 56
86% less call options, than puts
Call options by funds: $546K | Put options by funds: $4.01M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target | 75%upside $8 | Buy Reiterated | 18 Oct 2024 |
Financial journalist opinion
Based on 4 articles about AMLX published over the past 30 days
